Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu 210008, China.
Chin Med J (Engl). 2022 Jul 20;135(14):1653-1663. doi: 10.1097/CM9.0000000000002310.
Chronic hepatitis B (CHB) virus infection is an important threat to global health despite the administration of vaccines and the use of antiviral treatments. In recent years, as the prevalence of obesity and metabolic syndrome has increased, non-alcoholic fatty liver disease (NAFLD) in patients with CHB has become more common. Both diseases can lead to liver fibrosis and even hepatocellular carcinoma, but the risk of dual etiology, outcome, and CHB combined with NAFLD is not fully elucidated. In this review, we assess the overlapping prevalence of NAFLD and CHB, summarize recent studies of clinical and basic research related to potential interactions, and evaluate the progressive changes of treatments for CHB patients with NAFLD. This review increases the understanding of the relationship and mechanisms of interaction between steatosis and hepatitis B virus infection, and it provides new strategies for the future clinical management and treatment of CHB combined with NAFLD.
慢性乙型肝炎（CHB）病毒感染是全球健康的重要威胁，尽管疫苗接种和抗病毒治疗的应用已经得到普及。近年来，随着肥胖和代谢综合征的流行率增加，CHB 患者中的非酒精性脂肪性肝病（NAFLD）变得更加普遍。这两种疾病都可能导致肝纤维化，甚至肝细胞癌，但双重病因、结局以及 CHB 合并 NAFLD 的风险尚未完全阐明。在这篇综述中，我们评估了 NAFLD 和 CHB 的重叠流行率，总结了最近关于潜在相互作用的临床和基础研究，并评估了治疗 CHB 合并 NAFLD 患者的治疗方法的进展变化。本综述增加了对脂肪变性和乙型肝炎病毒感染之间关系和相互作用机制的理解，并为未来 CHB 合并 NAFLD 的临床管理和治疗提供了新策略。
